MediPharm Labs Q3 revenue up 17% on medical cannabis demand

Medipharm Labs

13/11/2025 13:09

Overview

MediPharm Labs Q3 2025 revenue grows 17% yr/yr

Operating expenses decreased 19% yr/yr, contributing to increased cash balance

Outlook

MediPharm plans to launch inhalers in international markets, including the UK

Company focuses on international medical cannabis market expansion

MediPharm aims to enhance profitability by streamlining expenses

Result Drivers

INTERNATIONAL SALES - 83% yr/yr growth in international medical cannabis revenue, now 56% of total revenue

COST MANAGEMENT - Operating expenses decreased 19% yr/yr, contributing to increased cash balance

PRODUCT EXPANSION - Expanded inhaler line in domestic market and launched metered dose inhalers in Australia

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
C$11.40 mln
C$11.90 mln (1 Analyst)
Q3 Adjusted EBITDA
Miss
-C$1.10 mln
C$443,000 (1 Analyst)

Analyst Coverage

The one available analyst rating on the shares is "hold"

The average consensus recommendation for the pharmaceuticals peer group is "buy."

Press Release: ID:nGNXb0cM1B

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)